AnPac Bio-Medical Science Co., Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANPC research report →
Companywww.anpacbio.com
AnPac Bio-Medical Science Co. , Ltd. , a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China.
- CEO
- Chris Chang Yu
- IPO
- 2020
- Employees
- 89
- HQ
- Lishui, CN
Price Chart
Valuation
- Market Cap
- $26.97M
- P/E
- -0.54
- P/S
- 15.23
- P/B
- -4.09
- EV/EBITDA
- -1.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.21%
- Op Margin
- -698.59%
- Net Margin
- -860.16%
- ROE
- 1140.01%
- ROIC
- -2066.24%
Growth & Income
- Revenue
- $12.04M · -33.04%
- Net Income
- $-103,598,000 · 13.73%
- EPS
- $-54.18 · 69.31%
- Op Income
- $-84,138,000
- FCF YoY
- 25.14%
Performance & Tape
- 52W High
- $11.99
- 52W Low
- $2.60
- 50D MA
- $5.05
- 200D MA
- $5.35
- Beta
- 1.56
- Avg Volume
- 22.07K
Get TickerSpark's AI analysis on ANPC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 24 | Xu Haohan | other | 0 |
| Jan 1, 24 | Xu Haohan | other | 0 |
Our ANPC Coverage
We haven't published any research on ANPC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANPC Report →